Logistics companies are making substantial investments to expand their capacity for shipping temperature-sensitive medications, driven by growing demand for GLP-1 drugs used in weight loss and diabetes treatment. According to a recent Gallup poll, 11% of Americans are currently taking GLP-1 medications for weight loss, a significant increase from 3% two years prior. Most major GLP-1 products, including medications from Novo Nordisk and Eli Lilly, require refrigerated storage and shipment to maintain their effectiveness.
UPS invested $48 million in temperature-controlled facilities earlier this month as part of its broader healthcare logistics expansion. The company’s healthcare division achieved its first $3 billion quarterly revenue in the opening quarter of this year and has consistently gained market share since 2021. According to growth projections, the market for temperature-sensitive biologics is expected to expand at an 8.3% annual rate through 2033, potentially reaching a value of approximately $39.1 billion. The primary challenge in this sector involves maintaining precise temperature conditions throughout the entire supply chain, as even brief deviations can compromise medication quality.
FedEx recently launched a dedicated life sciences organization to focus on pharmaceutical distribution and reported healthcare transportation revenue of nearly $10 billion in fiscal 2026. The company is leveraging machine learning technology and specialized tracking systems to monitor product movement and ensure proper handling. C.H. Robinson surpassed $1 billion in healthcare logistics revenue over the past year, largely attributable to GLP-1 growth, while DHL Supply Chain is investing 2 billion euros by 2030 to strengthen its health logistics capabilities.
Logistics providers emphasize that the complexity of modern pharmaceutical supply chains extends beyond temperature control. Many medications have limited shelf lives and require delivery within specific time windows. Competition for limited refrigerated transportation resources has intensified, and logistics companies are working with pharmaceutical manufacturers to develop longer shelf-life formulations and more efficient distribution methods. Industry leaders stress the critical importance of end-to-end visibility and reliability, given that medications cannot be replaced if lost or damaged during shipment.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI